Mainzer Modell.de  
DeutschEnglish
/ Projekte / Antiallergika 
Printversion
letzte Änderung am 22.09.2006

Antiallergika

Studienergebnisse aus dem Jahr 2006 sind hier in einem englischen Abstract zusammengefasst:

 

 

IS ASTHMATIC TREATMENT DURING PREGNANCY SAVE FOR THE INFANT?

AN ANALYSES OF 51,345 INFANTS OF THE BIRTH REGISTRY MAINZ MODEL


Study objective

Until today maternal drug therapy for chronic asthma is under discussion for adverse fetal outcome. Most studies reflect a lack in power or standardization to give strong evidence in favor or against a teratogenic effect of continuous maternal asthma treatment and during the first trimester.

Material and methods

During the study period (1990-2004) 51,345 newborn were registered in the birth registry of Rheinhessen. All neonates underwent standardized examinations and anamnestic data (e.g. maternal medication) were collected six weeks prior to birth. Newborn/fetuses with major malformations (MM) were defined as cases, all other infants as controls. Case-control analyses were performed and relative risks calculated as odds ratios (OR) with 95% confidence intervals (CI).

Results

For the diagnosis of chronic asthma 217 infants/fetuses (1990 – 2004) were exposed to at least one of the three drug categories antiallergics, bronchospasmolytic agents, or glucocorticosteroids (oral and inhaled). In the population-based birth cohort 81 infants were exposed to maternal antiallergic medication (10 with MM; 12%), 157 to bronchospasmolytics (18 with MM; 11%) and 102 to corticoids (9 with MM; 9%). Only the bronchspasmolytics showed statistical significance for MM (p=0.036, OR 1.7, CI 1.03-2.8). Analyzing these 157 infants in the sub-groups β2-agonists (n=144), parasympatholytics (n=35), and theophyline (n=22) statistical significance was only achieved in the first group (p=0.012, OR 1.9, CI 1.1-3.1). Testing mono therapy by β2-agonists (n=41) and all other used combinations with an β2-agonist, significance only remained for mono therapy (p=0.014, OR 2.7, CI 1.2-6.0). The β2-agonists were entered in a logistic regression model together with other known causal risk factors for congenital malformations and remained stable with an increased risk OR 1.9, CI 1.1-3.1. Within the group of congenital malformations especially the internal urogenital system was affected by maternal intake of β2-agonists (OR 3.2, CI 1.5-6.8).

Conclusions

This analysis indicates a possible relation between maternal intake of β2-agonists within the first trimester and congenital malformations. Further epidemiological studies are necessary to corroborate or neglect these results.